Corient Private Wealth LP Invests $17.06 Million in Avantor, Inc. $AVTR

Key Points

• Corient Private Wealth acquired 1.72 million Avantor shares worth approximately $17.06 million, representing about 0.25% of the company. Institutional investors collectively own 95.08% of Avantor.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and a $12.00 average price target; ratings include two Buys, 15 Holds, and one Sell.
• Avantor reported quarterly EPS of $0.21, exceeding the $0.19 estimate, while revenue reached $1.69 billion versus the $1.61 billion consensus. The stock opened at $14.60, near its 52-week high of $15.93.

Corient Private Wealth LP acquired a new position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,722,983 shares of the company's stock, valued at approximately $17,058,000. Corient Private Wealth LP owned approximately 0.25% of Avantor as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently bought and sold shares of AVTR. Bank of America Corp DE acquired a new position in Avantor during the 2nd quarter worth approximately $108,795,000. Freestone Grove Partners LP acquired a new position in Avantor during the second quarter worth $56,577,000. Man Group plc bought a new position in Avantor in the second quarter valued at $9,806,000. Jupiter Topco LLC acquired a new stake in Avantor in the 2nd quarter valued at $3,047,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Avantor in the 2nd quarter valued at $1,287,000. Institutional investors own 95.08% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Sanford C. Bernstein assumed coverage on shares of Avantor in a research note on Friday, June 26th. They set a "market perform" rating and a $10.50 price objective for the company. Barclays upped their target price on Avantor from $7.00 to $8.00 and gave the stock an "underweight" rating in a report on Wednesday, June 24th. Wolfe Research raised Avantor from a "strong sell" rating to a "hold" rating in a research report on Thursday, July 30th. Stifel Nicolaus upped their price objective on Avantor from $8.00 to $15.00 and gave the stock a "hold" rating in a research note on Thursday, July 30th. Finally, Wells Fargo & Company boosted their target price on shares of Avantor from $14.00 to $16.00 and gave the stock an "overweight" rating in a report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $12.00.

Avantor Stock Down 0.1%

AVTR stock opened at $14.60 on Friday. Avantor, Inc. has a 1-year low of $7.26 and a 1-year high of $15.93. The business's 50 day simple moving average is $12.12 and its 200 day simple moving average is $9.77. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $9.87 billion, a PE ratio of -17.38, a PEG ratio of 11.03 and a beta of 0.89.

Avantor (NYSE:AVTR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The business had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.61 billion. During the same quarter last year, the firm posted $0.24 EPS. The company's quarterly revenue was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, research analysts anticipate that Avantor, Inc. will post 0.81 EPS for the current year.

About Avantor

Avantor, Inc NYSE: AVTR is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor's offerings are organized across two primary segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source